Biotech Values

[DewDiligence]

Agree—this is the worst-case scenario. The Lovenox patent-infringement lawsuit still holds some value for MNTA, but the lawsuit’s NPV for MNTA is greatly reduced with a settlement presumably off the table.

Support for the shape price will now have to come from the fact that the enterprise value (market cap less cash on hand) is very low, even if one values the NPV of the Lovenox royalty stream very conservatively.